Bioanalytical Services

What is Bioanalysis?

What Is Bioanalysis

What is Bioanalysis?

Bioanalysis is a specialized branch of analytical chemistry that aims to quantify the concentration of a drug, metabolite, or biomarker in a biological matrix such as blood, serum, plasma, urine, or tissue samples.

Additionally, for large biomolecules, bioanalytical assays are frequently performed to evaluate the immunogenicity of the drug.

When Are Bioanalytical Studies Needed in Drug Development?

Bioanalysis Infographic Emery Pharma
Bioanalysis Infographic
  • Bioequivalence Icon


  • Biomarkers Icon


  • Pharmacokinetics Icon

    Pharmacokinetics (PK)

  • Toxicokinetics Icon


  • Bioavailability Icon


Bioanalytical studies are critical in any drug discovery and development program. Studies that require bioanalytical support include bioavailability (BA)/bioequivalence (BE), non-clinical pharmacokinetics (PK)/toxicokinetics (TK), anti-drug antibody assays (ADA), and biomarker evaluation. Guidelines for these studies have been outlined by the FDA, ICH, EMA, and other global regulatory bodies.

Emery Pharma Can Help

with Your Discovery and Development Programs

Reliable bioanalytical assays require robust method development and validation. At Emery Pharma, we utilize sophisticated techniques to help our Clients’ with their bioanalysis needs in support of all stages of drug discovery and development programs.

Molecule Product Type Icon Default

Small Molecules

We specialize in LC-MS/MS method development and validation, including multi-component analysis, pro-drugs, metabolites, photo-, and temperature-sensitive compounds.

Biologics Default


We provide ELISA, anti-drug antibody assays (ADA), immunogenicity, neutralizing antibody assays (NAb), multiplexed ligand binding assays (e.g., MSD), LC-MS/MS, and immunoaffinity-based LC-MS assays.

Stage Of Development Default

Stage of Development

We support programs across discovery, pre-clinical studies, clinical trials (Phase I, II, and III), and regulatory submissions across the globe.

Bioanalytical Services Default

Services Offered

Services include study design, de novo bioanalytical method development, sample cleanup/preparation, qualification, GLP-level validation, and sample analysis.

What Are the Challenges in Bioanalysis?

For many scientists, bioanalytical method development, validation, and reporting may seem like a ‘black box’ – as it necessitates an intuitive understanding of how analytes behave in an ever-evolving complex biological matrix. Utilizing a customized approach, our team has the experience to face every challenge that comes our way. We are perfectly suited to handle all of the following challenging aspects about Bioanalysis.

We are happy to be the partnering lab for Clients requiring analysis for such hard-to-solve problems by sharing our extensive technical knowledge and experience. Please contact us today to learn more about our services and let us know how we can be your bridge to success on your next bioanalysis project.

  • Robust Methods Icon

    Robust Methods

    Requirement for robust methods that work with many different sample types and background matrices, such as blood/plasma/serum, various tissues, and samples from both pre-clinical and clinical setting.

  • Unpredictable Samples Icon

    Processing Unpredictable Samples

    Processing samples derived from unknown genetic, metabolic, and dietary makeup, which pose unpredictability during analysis.

  • Sophisticated Instrumentation Icon

    Sophisticated Instrumentation

    Employing sophisticated instrumentation such as triple quadrupole mass spectrometers that require specialized training.

  • GLP Guidelines Icon

    Adherence to GLP Guidelines

    Submissions with phase-appropriately validated methods that adhere to GLP guidelines described in 21CFR58, Good Laboratory Practice for Nonclinical Laboratory Studies.

  • Industry Standards Icon

    Familiarity with Industry Standards

    Familiarity with Regional differences in guidance and acceptance standards for various regulatory bodies (FDA in the United States, EMA in Europe, ANVISA in Brazil, etc.) that are updated regularly.